FDA Halts REGENXBIO's MPS Gene Therapies Over Tumor Concern
Event summary
- FDA placed clinical holds on REGENXBIO's RGX-111 (MPS I) and RGX-121 (MPS II) programs after a single case of intraventricular CNS tumor in an RGX-111 participant.
- The tumor was detected during a routine MRI of a 5-year-old participant treated four years prior with RGX-111.
- No evidence of neoplasm reported in other participants treated with RGX-111 (n=9) or RGX-121 (n=32).
- REGENXBIO disputes FDA's decision to halt RGX-121, citing its positive safety profile in over 30 patients.
The big picture
The FDA's clinical hold highlights the regulatory scrutiny facing gene therapies, particularly those targeting ultra-rare diseases with limited treatment options. REGENXBIO's ability to navigate this challenge will be critical for its pipeline, which includes collaborations with major pharma players. The case underscores the balance between innovation and patient safety in the gene therapy space.
What we're watching
- Regulatory Headwinds
- Whether FDA's broad clinical hold on RGX-121 will delay potential approval and commercialization for MPS II.
- Clinical Risk
- The pace at which REGENXBIO can resolve the tumor investigation and resume trials for both MPS programs.
- Strategic Impact
- How this setback affects REGENXBIO's partnerships with Nippon Shinyaku and AbbVie for other gene therapy programs.
Related topics